Abstract: Compounds and compositions are described herein that inhibit the biosynthesis of mycotoxins and fungal sporulation. Such compounds and compositions are useful for inhibiting mold. Methods of using such compounds and compositions are also described herein that involve applying the compositions to plants, plant parts, structures, containers, and other surfaces.

Abstract: Compounds and compositions are described herein that inhibit the biosynthesis of mycotoxins and fungal sporulation. Such compounds and compositions are useful for inhibiting mold. Methods of using such compounds and compositions are also described herein that involve applying the compositions to plants, plant parts, structures, containers, and other surfaces.

Abstract: A process is provided for inhibition of neural damage associated with an ischemic event that includes the administration of anthocyanin compound to a subject. After allowing sufficient time for the anthocyanin compound to reach the situs of the ischemic event, inhibition of neural damage associated with the ischemic event occurs. Neural damage is further inhibited by administration of the anthocyanin compound in conjunction with an agent effective in and specifically including tissue plasminogen activator. The anthocyanin compound in specific embodiments is in pure form or a mixture of two or more anthocyanins, or anthocyanidins or aglycones thereof, with the mixture being a natural product extract. A composition is also provided that includes ananthocyanin compound to cause blood clot dissolution. The agent being in specific embodiments is tissue plasminogen activator or aspirin.

Abstract: The present invention describes food supplements that contain one or more fruit extracts useful for pain relief and anti-inflammation. The food supplements may be used to inhibit inflammation mediated by cyclooxygenase and more particularly by cyclooxygenase-2.

Abstract: A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient.

Abstract: A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient.

Abstract: A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient.

Abstract: A method for the treatment of obesity, diabetes, high cholesterol and related diseases including hyperglycemia, lipid disorders, hyperglyceridemia, dyslipidemia and atherosclerosis in mammals using anthocyanins, anthocyanidins, ursolic acid and/or betulinic acid is described. Compositions adapted for these treatments are also described.

Abstract: A method for stimulating insulin secretion by anthocyanidins and anthocyanins is described. The secretion can be in vivo in mammals, including humans, or in vitro.

Abstract: A process for the preparation of hydroxyl substituted anthraquinones is described. The process couples a phthalic anhydride (substituted or unsubstituted) to benzene ring moiety substituted with at least two hydroxyl groups. Remaining hydroxy groups were converted to methoxy groups in some anthraquinones. The compounds are particularly useful for the treatment of parasitic diseases. Also, a method of treating or preventing malaria, filariasis schistosomiasis and other parasitic diseases using anthraquinones.

Abstract: A method for inhibiting of COX2 and inflammation by administering a hydroxybenzaldehyde.

Abstract: A composition for the treatment of onychomycosis (fungal nail disease) is described. The composition consists essentially of thymol, camphor, menthol and Eucalyptus citridiora as a colorless liquid oil without any carrier or solvent for these ingredients.

Abstract: Novel isolated and purified withanamides and withanolides are described. In particular, compounds from Withania somnifera fruit are the preferred source of the withanamides and withanolides, although they can be from other plant sources. In addition to their use as powerful antioxidants, the withanamides and withanolides can be useful for the treatment of depression, Alzheimer's Disease, obesity and migraine headaches.

Abstract: Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1.

Abstract: Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1.

Abstract: Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1.

Abstract: Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1.

Abstract: Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1.

Abstract: Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1.

Abstract: Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1.